Featured Research

from universities, journals, and other organizations

Referring doctors increasingly aware of deep brain stimulation therapy; more work remains

Date:
August 16, 2011
Source:
Cedars-Sinai Medical Center
Summary:
While deep brain stimulation has gained recognition by referring physicians as a treatment for Parkinson's disease and other movement disorders, just half of the patients they recommend are appropriate candidates to begin this relatively new therapy immediately, researchers say.

While deep brain stimulation has gained recognition by referring physicians as a treatment for Parkinson's disease and other movement disorders, just half of the patients they recommend are appropriate candidates to begin this relatively new therapy immediately, researchers at Cedars-Sinai Medical Center in Los Angeles and The Mount Sinai Medical Center in New York say.

They looked back to a 2004 study, which found that just 5 percent of referrals then were good candidates; they compared their new figures and surmised that referring physicians have increased their awareness and acceptance of deep brain stimulation, a therapy in which electrical leads, linked to a control device, are surgically and precisely implanted to modulate defective nerve signals in the brain to calm symptoms of Parkinson's and other movement disorders.

But physicians still often refer patients for this therapy before other treatment options have been exhausted or because they have unrealistically high expectations for it, said Michele Tagliati, MD, director of the Movement Disorders Program at Cedars-Sinai's Department of Neurology. He is senior author of an Aug. 11 Archives of Neurology article and an expert in device programming, which fine-tunes stimulation for individual patients.

Of 197 patients referred for evaluation for deep brain stimulation, 50 percent were found to be good candidates for immediate therapy, 25 percent were possible future candidates and 24 percent were poor candidates because of other neurological or medical conditions. Analyzing the referral sources -- movement disorder specialists, primary care physicians, general neurologists, other physicians and patients -- the researchers found that movement disorder specialists referred more patients and most were good therapy candidates.

Over the four-year study period, which ended in late 2009, researchers noted that the number of patients referred for DBS therapy at earlier stages of the disease increased. "The study does not address this change specifically and we have no proof, but we speculate that doctors became more liberal in sending patients for surgery for deep brain stimulation," Tagliati said. "Maybe they are accepting this therapy more and sending patients earlier for it instead of at the very end stage of disease. While doctors may be sending some patients too early to be treated immediately with DBS therapy, it's better to see these patients too early than too late. As long as they're evaluated in a responsible, reputable movement disorders center, they can be reevaluated months or even years later and have the surgery appropriately timed. It isn't always clear exactly what is the right time for this therapy, but especially for Parkinson's disease, if the patient is amenable to medication changes, it is not appropriate to jump to the surgery right away."

Deep brain stimulation was approved by the Food and Drug Administration for essential tremor in 1997, Parkinson's disease in 2002, dystonia in 2003 and extreme cases of obsessive-compulsive disorder in 2009.


Story Source:

The above story is based on materials provided by Cedars-Sinai Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. Katz, C. Kilbane, J. Rosengard, R. L. Alterman, M. Tagliati. Referring Patients for Deep Brain Stimulation: An Improving Practice. Archives of Neurology, 2011; 68 (8): 1027 DOI: 10.1001/archneurol.2011.151

Cite This Page:

Cedars-Sinai Medical Center. "Referring doctors increasingly aware of deep brain stimulation therapy; more work remains." ScienceDaily. ScienceDaily, 16 August 2011. <www.sciencedaily.com/releases/2011/08/110816112155.htm>.
Cedars-Sinai Medical Center. (2011, August 16). Referring doctors increasingly aware of deep brain stimulation therapy; more work remains. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2011/08/110816112155.htm
Cedars-Sinai Medical Center. "Referring doctors increasingly aware of deep brain stimulation therapy; more work remains." ScienceDaily. www.sciencedaily.com/releases/2011/08/110816112155.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins